Samsung Medical Center: Lung Neoplasms trials

The registry lists 49 Lung Neoplasms studies with Samsung Medical Center as lead sponsor. 5 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 22Phase 3 5Phase 4 1No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Mechanical Power-based Lung-protective Ventilation During One-lung VentilationNot yet recruitingNCT07772804Not applicable
• Anesthesia and Non-small Cell Lung Cancer RecurrenceRecruitingNCT06330038Phase 4
• Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)RecruitingNCT04591002Phase 2
• Cell Free DNA for the Diagnosis and Treatment in Early NSCLCRecruitingNCT03791034
• Genomic Analysis to Identify a Predictive Biomarker for ImmunotherapyRecruitingNCT03578185
• Annual Brain MRI Surveillance for Detection of Brain Metastasis in Patients With Lung CancerCompletedNCT07646041
• Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. SulfonylureasCompletedNCT07332156
• Lazertinib 160mg in EGFR T790M NSCLCStatus unknownNCT05701384Phase 2
• Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer SurvivorsStatus unknownNCT05078918Not applicable
• Practical Usability of EGFR Mutation Detection in ctDNA From Resectable NSCLCStatus unknownNCT04922073
• Central Nervous System(CNS) Efficacy of DacomitinibStatus unknownNCT04675008Phase 2
• Liquid Biopsy Using Methylation Sequencing for Lung CancerCompletedNCT04253509
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3
• The Impact of Physical Activity on the Postoperative Symptoms, Complications, and Quality of Life Among Lung CancerActive, not recruitingNCT03705546
• Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 InhibitorsStatus unknownNCT03656094Phase 2
• Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLCStatus unknownNCT03616691Phase 2
• Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung CancerStatus unknownNCT03585998Phase 2
• Liquid Biopsy in Lung CancerCompletedNCT03479099
• Uncommon EGFR AZD9291Status unknownNCT03424759Phase 2
• The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR MutationStatus unknownNCT03399669Phase 2
• AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]TerminatedNCT03366675Phase 2
• Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMSStatus unknownNCT03257124Phase 2
• Development of Patient Tailored Guideline of Physical Activity for Lung CancerStatus unknownNCT03215537Not applicable
• Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR AmplificationTerminatedNCT03106155Phase 2
• Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung CancerActive, not recruitingNCT03066297
• Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer PatientsStatus unknownNCT03053856Phase 2
• Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A MutationsCompletedNCT03009682Phase 2
• Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or GefitinibCompletedNCT02747953Phase 2
• Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 MutationTerminatedNCT02688907Phase 2
• Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer PatientsCompletedNCT02593019Phase 2
• Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?CompletedNCT02331056
• Personalized Sequence for Thoracic, Esophageal, and H&N CancerStatus unknownNCT02299622
• Vandetanib in Advanced NSCLC With RET RearrangementCompletedNCT01823068Phase 2
• Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA AnalysisStatus unknownNCT01776684Not applicable
• Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic BiomarkersStatus unknownNCT01585545
• Feasibility of Mutational Analysis of Non-Small Cell Lung Cancer (NSCLC) Using Low-volume Lung AspiratesWithdrawnNCT01482572
• Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving ChemotherapyCompletedNCT01482182
• Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase ExpressionStatus unknownNCT01401192Phase 2
• Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)Status unknownNCT01312337Phase 2
• Chemotherapy With or Without Radiosurgery for Asymptomatic Oligo Brain MetastasisStatus unknownNCT01301560Phase 3
• The Continuation of ErlotinibStatus unknownNCT01130779Phase 2
• Asymptomatic Brain Metastasis in Non-small Cell Lung Cancer (NSCLC)Status unknownNCT01130766Phase 3
• Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung CancerCompletedNCT01130753Phase 2
• Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung CancerCompletedNCT01125995Phase 3
• Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)CompletedNCT01079520Not applicable
• Combination Anticancer Therapy of Paclitaxel and Everolimus for Relapsed or Refractory Small Cell Lung CancerCompletedNCT01079481Phase 1
• Adjuvant CCRT vs CT in Minimal N2 NSCLCCompletedNCT01066234Phase 2
• Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyStatus unknownNCT01066195Phase 3
• Whole-Body Magnetic Resonance Imaging/Positron Emission Tomography (MRI/PET) in the Staging of Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT01065415